Skip to content

2APharma

Biopharmaceutical company

  • Home
  • ABOUT US
  • VACCINE PLATFORM
  • PIPELINE
    • OVERVIEW
    • 2AP01
    • 2AP02
    • 2AP03
    • 2AP05
    • 2AP07
  • NEWS
  • CONTACT US

Illustration of Human Papillomavirus with conserved L2 minor capsid protein in centres of L1 pentame

June 5, 2020

2Ap01

OVERVIEW:

  • Broader coverage than approved HPV vaccines
  • Formulated without adjuvants
  • Low production cost
  • First-in-human, clinical phase 1 trial finished
  • The global market for prophylactic HPV vaccines is likely to grow rapidly as more and more countries expand national vaccination programs to include HPV vaccinations not only for girls but also for boys. In addition, it is now estimated that 60-70% of oropharyngeal cancers are caused by HPV virus infections, opening up a discussion on HPV vaccinations for adults too.
    More than 170 types of Human Papillomavirus have been fully sequenced and there are many more to be investigated. The most advanced approved HPV vaccine provides protection against nine HPV types. In pre-clinical tests, 2A Pharma’s HPV vaccine candidate, formulated without adjuvant, has been shown to provide protection against more than 20 HPV types (and we are still testing), including several that can cause both mucosal and cutaneous cancers in which existing vaccines do not protect against.

    Back

    Denmark

    2A Pharma ApS
    Niels Jernes Vej 10
    9220 Aalborg Øst
    Denmark

    CVR No.: 3939 1597
    VAT No.: DK 3939 1597

    Sweden

    2A Pharma AB
    Södergatan 3
    211 34 Malmö
    Sweden

    Registration No.: 559090-2788
    VAT No.: SE55 9090 2788 01

    Pipeline

  • 2AP01 HPV
  • 2AP02 Breast Cancer
  • 2AP03 Allergic Diseases
  • 2AP04 Alzheimer's
  • 2AP05 Autoimmune Diseases
  • 2AP06 HIV
  • 2AP07 Head and Neck Cancer
  • Subscribe to our newsletters

    Contact

    +45 7214 6700
    info@2apharma.com